Home›Rifampin›Rifampin + Ticagrelor

Does Rifampin Interact with Ticagrelor?

Rifampin and Ticagrelor have a contraindicated drug interaction according to U.S. FDA drug labeling data. Strong CYP3A inducer that substantially reduces ticagrelor exposure and decreases efficacy. The mechanism involves cyp3a induction. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This information is based on official FDA drug labeling sourced from OpenFDA and the NIH National Library of Medicine.

Severity
Contraindicated
Rifampin Class
Rifamycin Antibacterial
Ticagrelor Class
P2Y12 Platelet Inhibitor
Management
Do not take together
Data Source
U.S. FDA via OpenFDA

How This Interaction Works

The interaction between Rifampin and Ticagrelor occurs because cyp3a induction. Clinically, this means strong cyp3a inducer that substantially reduces ticagrelor exposure and decreases efficacy. Because of the severity of this interaction, these medications are contraindicated — meaning they should not be taken together under any circumstances. If you are currently taking both, contact your healthcare provider immediately to discuss alternatives.

What To Tell Your Doctor or Pharmacist

If you are taking Rifampin and your doctor is considering prescribing Ticagrelor (or vice versa), make sure to:

  • Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
  • Ask whether the benefits of combining these medications outweigh the risks for your specific situation
  • Ask what symptoms to watch for that would indicate the interaction is causing problems
  • Ask about alternative medications that do not interact with your current regimen
  • Ask how frequently you should be monitored while these are co-prescribed
  • Never stop or change either medication without first consulting your healthcare provider
💊 Rifampin(Rifadin)+💊 Ticagrelor(Brilinta)

Severity & Interaction Details

⛔
contraindicated
Avoid this combination
FDA labeling lists this pair as contraindicated. The risk outweighs the benefit in nearly all cases.
Severity scale
MinorContra
On record
Yes
Drug A class
Rifamycin Antibacterial
Drug B class
P2Y12 Platelet Inhibitor
Source
NLP:ticagrelor

What this means in plain English

Strong CYP3A inducer that substantially reduces ticagrelor exposure and decreases efficacy.

About Rifampin and Ticagrelor

Rifampin is a Rifamycin Antibacterial, while Ticagrelor is a P2Y12 Platelet Inhibitor. You may recognize them by the brand names Rifadin and Brilinta. Both medications are taken by mouth. Ticagrelor additionally carries an FDA boxed warning, the FDA's strongest safety alert.

What the FDA label says

"CYP3A induction"

📖 Source: NLP:ticagrelor

Recent research & FDA safety updates

Live

Auto-aggregated from PubMed E-utilities and FDA safety data.

Share this result:

WhatsAppText / SMSEmail
Also share on:XFacebook
Add more drugs
Check Rifampin and Ticagrelor against your full medication list

Most patients take more than two medications. CDI checks every pair across up to 20 drugs simultaneously — including OTCs and common supplements.

Add more drugs →
Data integrity: Every interaction shown is extracted directly from official U.S. FDA drug labeling via openFDA and the U.S. National Library of Medicine (NIH) — no interactions are invented, inferred, or manually edited. Maintained by CheckDrugInteractions.com. See our methodology or report a correction at support@checkdruginteractions.com.

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine, supplemented with a small number of well-established interactions from curated clinical references. For informational purposes only. Always consult your pharmacist or physician.